Trial intelligence / Profile preview

Open-label phase Ib study of motixafortide (BL-8040) for viral ARDS

MOH_2020-11-22_009529Phase 2Recruiting

Sponsor: ד"ר יסמין מאור
Start: Nov 2020
Modality: Peptides
Countries: 1

Overview

Phase 2, open-label, single-arm trial of motixafortide in acute respiratory distress syndrome (ARDS), sponsored by ד"ר יסמין מאור. Primary endpoint: Safety and tolerability of motixafortide. Started Nov 2020; status: recruiting.

Drugs

motixafortide

Conditions

acute respiratory distress syndrome (ARDS)

Beyond the preview

Go deeper on MOH_2020-11-22_009529.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on MOH_2020-11-22_009529.